Moreover, a significant upregulation of ZC3 has been observed in KRAS-mutant lung adenocarcinomas (Grzeskowiak et al., 2018), where KRAS mutations are frequently observed molecular alterations in non-small cell lung cancers and serve as a predictor of poor prognosis (Buscail et al., 2020). This evidence concerns the gene KRAS and non-small cell lung carcinoma.